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ABSTRACT
Background. Local tumor progression (LTP) is a serious
complication after local ablation of malignant liver tumors,
negatively influencing patient survival. LTP may be the
result of incomplete ablation of the treated tumor. In this
study, we determined whether viable tumor cells attached
to the needle applicator after ablation was associated with
LTP and disease-free survival.
Methods. In this prospective study, tissue was collected of
96 consecutive patients who underwent local liver abla-
tions for 130 liver malignancies. Cells and tissue attached
to the needle applicators were analyzed for viability using
glucose-6-phosphate-dehydrogenase staining and auto-
fluorescence intensity levels of H&E stained sections.
Patients were followed-up until disease progression.
Results. Viable tumor cells were found on the needle
applicators after local ablation in 26.7% of patients. The
type of needle applicator used, an open approach, and the
omission of track ablation were significantly correlated
with viable tumor tissue adherent to the needle applicator.
The presence of viable cells was an independent predictor
of LTP. The attachment of viable cells to the needle
applicators was associated with a shorter time to LTP.
Conclusions. Viable tumor cells adherent to the needle
applicators were found after ablation of 26.7% of patients.
An independent risk factor for viable cells adherent to the
needle applicators is the omission of track ablation. We
recommend using only RFA devices that have track abla-
tion functionality. Adherence of viable tumor cells to the
needle applicator after local ablation was an independent
risk factor for LTP.
The most effective treatment for patients with primary
or metastatic liver tumors confined to the liver is surgical
resection.1,2 Because of improvements of imaging tech-
niques, expanded surgical possibilities, and effective
neoadjuvant treatment, liver resection is nowadays appli-
cable in an increasing amount of patients. Nevertheless, the
majority of patients with primary or metastatic hepatic
malignancies are unresectable. Local tumor destruction by
radiofrequency ablation (RFA) or laser-induced thermal
therapy (LITT) has proven to be a safe and effective
treatment in patients with unresectable liver malignan-
cies.3–7 Reported 5-year survival rates after local ablation
are 18–30% for tumors smaller than 4 cm.8–19
A major downside of RFA is local tumor progression
(LTP), which varies from 0–60% in literature.3,5,20–23
Large tumor size and a percutaneous approach have been
reported with a higher incidences of LTP according to a
meta-analysis of 5,224 treated liver tumors treated with
RFA.23 LTP usually is the result of incomplete ablation of
the treated tumor. Repositioning or withdrawal of the
needle applicator with insufficiently treated tumor cells
might cause implantation and outgrowth of tumor cells
along the tract of the needle applicator. Previously, Ohls-
son et al. 24 demonstrated the implantation and outgrowth
of tumor cells in 1% of patients with HCC and 10% of
patients with colorectal liver metastases after fine needle
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biopsy. In a previous paper on 40 patients who underwent
local ablation, we observed that tumor tissue was macro-
scopically visible on the needle applicator after 53% of all
applications, demonstrating displacement of tissue through
the liver during and after local ablation. Remarkably,
12.5% of the tumor cells attached to the needle applicator
were viable immediately after local tumor ablation.25
Therefore, we hypothesized that tumor dissemination
through attached viable cells on the needle applicator and
subsequent outgrowth of these cells along the needle
applicator track potentially threatens patient survival after
local ablation.
The purpose of this study was to determine the incidence
of viable tumor cells attached to needle applicators after
ablation and to assess whether the presence of viable tumor
cells correlated with LTP and disease-free survival (DFS).
MATERIAL AND METHODS
Needle applicators were collected after local ablation of
130 malignant liver tumors in 96 consecutive patients. All
130 liver malignancies of primary or secondary origin were
treated between November 2004 and November 2006
among seven centers in the Netherlands. The study protocol
was approved by the institutional ethical committees on
human research. Patients underwent standard staging before
treatment, including computed tomography of the abdomen.
All patient, tumor, and ablation characteristics were pro-
spectively collected using case report forms during and after
ablation and transferred to our prospective database.
Inclusion Criteria
Patients with unresectable primary or metastatic tumors
confined to the liver as decided by the surgeon and/or
radiologist were considered for this study. Patients
18 years or older who were amenable to RFA or LITT
treatment were included in the study.
Exclusion Criteria
Patients younger than 18 years, patients unfit for surgery,
patients with tumors adjacent to or infiltrating large ves-
sel(s), or patients with extrahepatic disease were excluded.
RFA/LITT PROCEDURE
In all treated tumors, the RFA electrode or laser fiber
was positioned in the centre of the tumor under ultrasound
or CT guidance with the goal to induce necrosis with a
circumferential necrotic rim of 0.5–1.0 cm. If necessary,
multiple overlapping applications were performed. RFA
was performed using three different commercially avail-
able RFA systems: the Radionics RF system (Covidien,
Mansfield, MA) consisting of a 500-kHz RF generator
connected to 15-G Radionics cool-tip mono- or triple-
needle applicator varying from 2 to 3 cm in active tip
(series 3 Radionics); the Radiotherapeutics RF system
(Natick, Boston Scientific MA) inducing a RF 2000 or
3000 generator system in combination with a 15-G LeVeen
needle applicator with deployable tines of 2.5–4 cm; and
the RITA RF system (RITA Medical Systems, Mountain
View, CA) consisting of the RITA RF model 1500 con-
nected to a 14-G Starbust XL needle applicator with
deployable tines of 2, 3, 4, or 5 cm.
LITT was applied using a neodymium:yttrium-alumi-
num-garnet (Nd:YAG) laser (Trumpf Medizine Systeme,
Umkirch, Germany) with a wavelength of 1,064 nm. All
surgeons preferred an open approach. A percutaneous
RFA/LITT was performed when the patient was not in
sufficient condition to undergo open surgery or had a small
easy accessible tumor. One center preferred percutaneous
RFA above open RFA. This center used CT guidance for
positioning of the needle applicator and subsequent control
of the ablation zone after RFA.
TISSUE COLLECTION
RFA electrodes and laser fibers were inspected immedi-
ately after retraction for the presence of macroscopic tissue
fragments. Subsequently, all electrodes and fibers were
rinsed and cleaned in a sterile tube containing Complete
Williams E (10% FCS, 1% Penicillin, Bio Whittaker Europe
and 1% Glutamine, Bio Whittaker Europe), within 10 min
after ablation. During transport, cells were maintained at
room temperature. After transportation, the cell suspension
was centrifuged for 10 min (21C, 50 g). Macroscopic tis-
sue fragments were fixed in 4% formaldehyde and
embedded in paraffin. Sections (3-4 lm) were stained with
hematoxylin and eosin staining (H&E staining). Remaining
cell suspensions were used for assembling cytospins, which
were stained with Papanicolaou (PAP) and Giemsa. Four
fortified cytospins were stored at -80C immediately after
use for later viability staining with glucose-6-phosphate-
dehydrogenase (G6PD). Samples collected later than
10 min after ablation, not collected in Complete Williams,
or not processed on the same day were excluded (Fig. 1).
DETERMINATION OF VIABILITY
Glucose-6-phosphate-diaphorase Staining
Glucose-6-phosphate-diaphorase is a cytosolic nicotin-
amide adenine catalyzing the initial step in the hexose
Viable Tumor Tissue Adherent to Needle Applicators after Local Ablation 3703
monophosphate shunt oxidizing glucose-6-phosphate to
phosphogluconolactone and reducing nicotinamide adenine
dinucleotide phosphate (NADP) to NADPH. The hydrogen
from reduced NADP reduces the nitro blue tetrazolium
(NBT) used forming NBT-formazan which results in a blue
color in viable cells.26,27 Defrosted cytospins were placed
in incubation medium for 15 min at 37C. The incubation
medium consisted of 10 mM of glucose-6-phosphate, 0.8
of mM NADP, 5 mM of sodium azide (NaN3), 5 mM of
magnesium chloride (MgCl2), 5 mM, 0.4 mM of 1-meth-
oxyphenazine methosulfate (mPMS), 5 mM of nitro blue
tetrazolium (NBT Polyscience, Northampton, UK), and
11% polyvinyl alcohol (PVA: Sigma-Aldrich, St Louis)
containing phosphate buffer (pH 7.45). After incubation,
slides were washed with 100 mM phosphate buffer for
3 min. Slides were mounted with glycerine and covered
with glass. Blue coloration of the cytoplasm indicated
viable cells. HepG2 cells were used as positive controls.
Incubations of HepG2 cells were performed in the same
medium without any substrate (glucose-6-phosphate).
Because G6PD is a cytosolic stain, the ratio between
nucleus size and cytoplasm size was compared with the
sizes in the Giemsa/Pap-stained cytospins of the same
application containing tumor cells.
Autofluorescence
Macroscopic tissue fragments were too small to fortify
cryostat sections and were therefore embedded in formalin
and fixed in paraffin disabling G6PD viability staining.
Because morphologically intact tumor cells might be a
result of heat fixation we added an autofluorescence
method described by Hennings et al. 28 to discriminate
between heat-fixed tissue and viable tumor tissue. Necrotic
cells are known to exhibit increased autofluorescence when
excited with light at 488 nm, as cellular autofluorescence
increases with decreasing metabolic activity.29–32
The study pathologist (FJWtK) determined whether H&E
sections contained intact tumor tissue. All H&E sections
containing intact tumor cells were examined for autofluo-
rescence using 488 nm wavelengths. To validate the method
described by Hennings et al. on tissue of liver tumors, we
compared autofluorescence intensities of biopsies contain-
ing viable tumor cells from CRLM and HCCs with biopsies
with known apoptotic or necrotic cells of CRLM and HCCs.
Biopsies were obtained immediately after resection and
snap-frozen in liquid nitrogen to maintain viability. H&E
slides were produced and examined under bright-field
microscopy using fluorescence microscopy for discrimina-
tion of necrotic or heat-fixed tissue and viable tissue. Images
were acquired using a Zeiss Axiovert 200 M microscope and
Zeiss LSM 510 Software. Unmodified photos were analyzed
using the Zeiss LSM 510 Software. Within each image, six
random areas were outlined by using the polygon function
and individually analyzed. Autofluorescence intensity was
determined by using the histogram function. The mean
fluorescence intensities with the 95% confidence interval
(CI) of viable tissue fragments (n = 30) and of dead tissue
fragments (n = 30) were determined to define the auto-
fluorescence intensities of viable and dead cells,
respectively. Mean autofluorescence intensity of the 30
areas of viable cells was 117 (95% CI, 80.139–154.02). The
maximum intensity measured in the 30 viable spots was 400.
Therefore intensities ranging from 0 to 400 were considered
to correspond with viable cells. Mean autofluorescence
intensity of the 30 areas that contained nonviable tissue was
1,462 (95% CI, 1443.78–1480.56).
Follow-up
Follow-up included abdominal and chest CT scanning
within the first month after RFA and thereafter at least every
6 months. Patients with a minimum follow-up of 1 year
were included in the survival analysis. Patients who under-
went repeated treatment because of technical failure or
transplantation within a year after ablation as well as patients
receiving adjuvant therapy were excluded from the survival
analysis. LTP was defined as tumor growth adjacent to the
original ablated tumor on CT scan. Time to LTP was defined
as the time between RFA and the first sign LTP. DFS was
defined as time between RFA and the first sign of recurrence.
Statistical Analysis
Univariate analysis using a chi-square test was per-
formed to see if any of the above-mentioned factors were
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FIG. 1 Flowchart study design
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associated with the presence of viable tumor cells on the
needle applicator. Possible factors related to LTP were
examined by using a multivariable logistic regression
analysis. Survival time was calculated by using the Kap-
lan–Meier survival function. A Cox regression analysis
was performed to determine risk factors for time to LTP
and DFS. For all analyses, P \ 0.05 was considered sta-
tistically significant. Statistical analyses were performed
using SPSS for Windows version 15.0 (SPSS, Chicago, IL).
RESULTS
During the study period, tissue was collected after
ablation in 96 patients (Fig. 1). In 21 patients, samples did
not fulfill the criteria for analysis after ablation. For patient
and tumor characteristics, see Table 1. Coagulation of the
needle track was not possible in case of the Radiothera-
peutics system used in this study (29 of 98 applications).
Track ablation also was not used in one other patient
treated with LITT because of subcapsular location of the
tumor. In all other procedures, track ablation was
performed.
Mean tumor size of the treated tumors was 3 cm (stan-
dard deviation 1.8). Vascular inflow occlusion (Pringle
maneuver) was used during ablation in 11 of 75 patients
(14.7%). The Pringle maneuver was used mostly by the
surgeon using LITT. This surgeon used the Pringle
maneuver in all of nine patients treated. Only two other
hospitals used the Pringle maneuver in two cases in which
the tumors were adjacent to large hepatic vessels.
Vital Tumor Cells after Local Ablation
Cytospins stained positive for viable tumor cells in 17 of
89 applications. Thirty-one sections were judged by the
study pathologist for presence of morphologically intact
tumor cells. Twenty-six sections showed low autofluores-
cence intensities indicating viable tumor tissue, whereas
five tumors demonstrated high autofluorescence intensities
indicating heat-fixed cells (Figs. 2, 3). The H&E slides
without morphologically intact cells all demonstrated high
([1,000) autofluorescence levels (results not shown). Of
the 75 patients treated, viable tumor cells were found after
treatment of 20 patients (26.7%). Three factors were
associated with adherence of viable tumor cells using a
univariate regression model (P \ 0.05): (1) the type of
electrode used (Radiotherapeutics electrode); (2) an open
approach; and (3) the omission of needle track ablation
after tumor ablation. The omission of track ablation
remained the only independent significant factor associated
with viable tumor cells on the needle applicator as deter-
mined with a multivariable regression model. There was a
significant correlation between the use of track ablation and
the use of a percutaneous approach (Spearman correlation
coefficient 0.393, P = 0). When an open approach was
used, track ablation was performed in 53% of applications.
When a percutaneous approach was used, track ablation
was used in 92% of applications. There also was a nearly
significant correlation between the needle applicator used
and the use of track ablation (Spearman correlation coef-
ficient 0.561, P = 0.064). Track ablation was applied
whenever possible. In two hospitals, the Radiotherapeutics
RF system was used. With this system, track ablation was
not possible (29 of 89 applications). With one other
application, concerning a subcapsular tumor treated with
TABLE 1 Patient and tumor characteristics
Total number of patients 75
No. of males 45 (60%)
No. of females 30 (40%)
Age (mean; SD) 65;13.19
Total number of tumors treated 118
Tissue collected of tumors 89
Tumor histology
HCC 18 (20.2%)
LM 71 (79.8%)
Differentiation primary tumor liver metastases (n = 71)
Good 1 (1.4%)
Moderate 54 (77.5%)
Poor 6 (8.5%)
Tumor diameter (mean; SD) 3 cm; 1.8
Local ablative technique
RFA 73 (82%)
LITT 16 (18%)
Tumor localization
Subcapsular 47 (55.3%)
Deep 38 (42.7%)
Approach
Open procedure 61 (68.5%)
Percutaneous 28 (31.5%)
Electrode
Radiotherapeutics 29 (32.6%)
RITA 16 (18%)
Radionics 28 (31.5%)
Laser fiber 16 (18%)
Track ablation
Yes 56 (62.9%)
No 30 (33.7%)
Missing 3 (3.4%)
Viable cells
Yes 26 (29.2%)
No 63 (70.8%)
SD standard deviation
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LITT, track ablation was not applied. In 59% of applica-
tions with the Radiotherapeutics applicator, viable cells
were found compared with 19, 11, and 19% for the RITA,
Radionics, and laser, respectively (Tables 2, 3).
LTP
Sixty-four patients had a follow-up of[1 year and were
included in the survival analysis (Fig. 1). LTP was found in
24 of 66 patients (36%). Mean time to LTP was 32.82
(95% CI, 27.49–37.26) months, whereas DFS was 12.5
(95% CI, 9.76–15.26).
Tumor size and viable cells attached to the needle
applicators were independent risk factors for LTP. Cox
regression analysis was used to determine risk factors for
time to LTP. Viable cells attached to the needle applicator
appeared to be an independent risk factor for a shorter time
to LTP. Furthermore, differentiation grade of the primary
tumor, tumor size, RFA electrode, and the omission of
track ablation were factors associated with a shorter time to
LTP in multivariate analysis (P = 0.01, 0.028, 0.001,
0.025, 0.028, respectively). The presence of viable cells
was not associated with a shortened DFS or overall sur-
vival. Mean overall survival in this study was 33 months
(Fig. 4).
DISCUSSION
The majority of patients with liver tumors have unre-
sectable disease. Local ablation permits a chance of 5-year
survival in case of small tumors (\4 cm). LTP is a major
problem after local ablative therapies, especially in large
tumors, as confirmed by this study demonstrating a local
recurrence rate of 38%.3,5,20–23 The local recurrence rate in
FIG. 2 a HE coupe of morphologically intact tumor cells and
stroma. b Black and white image of the same HE coupe, made with
confocal microscope without light. c Image of tumorcells excited with
light at 488 nm showing no autofluoresence (viable). d overlapping
image of (b) and (c)
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FIG. 3 Level of autofluorescence intensities. Autofluorescence intensities ranging from 0–400 were considered viable
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this observational study is high; however, it remains within
the reported range in literature (0–60%). This relatively
high rate might be due to the fact that only patients with a
minimum follow-up of 1 year were included in the analysis
for LTP.
Furthermore, the median follow-up time after ablation
was 34 months with five recurrences occurring far beyond
a year. Studies with a shorter follow-up period possibly
underestimate LTP rate. Another explanation could be that
the omission of track ablation was associated with a shorter
time to LTP, whereas in our study the rate of procedures
performed without track ablation was high. Tumor size also
influenced the LTP significantly. Of the patients with a
tumor smaller than 3 cm, 21% experienced LTP. Of the
patients with tumors larger than 3 cm, 64% experienced
LTP.
In this study, we detected viable tissue present on the
needle applicator after local ablation in 20 of 75 patients
(26.7%). Track ablation was the only significant factor in
the multivariable regression analysis that significantly
correlated with the presence of viable cells. Because track
ablation was not possible with the Radiotherapeutics sys-
tem, this system should be replaced with a system were
track ablation is possible.
Viable cells attached to the needle applicator were
associated with a higher risk of LTP and a shorter time to
LTP. DFS and overall survival were not affected, possibly
due to the small number (n = 64) of patients available for
survival analysis. These results show that local ablative
therapies do not always produce enough heat to annihilate
all tumor cells, creating a possibility for outgrowth of
residual tumor cells. Our study is in line with the results of
the study of Sofocleous et al., which demonstrated that
examination of tissue attached to the needle applicator is
feasible and can be used to predict LTP. In their study, they
stained tissue after RFA for HCC with KI-67 and caspase-3
staining.33 The immunohistochemical staining character-
istics of tumor may be preserved in heat-fixed tissue,
therefore, we used the autofluorescence method, which was
extensively described by Hennings et al. This method is
able to discriminate between heat-fixed tissue and viable
tumor tissue.28,34 Remarkably, this method showed viable
tissue in 26.7% of patients. The methods used to demon-
strate viability of cells in this study are a limitation because
they are not easy to apply in daily clinical practice. The
protocol for G6PD staining is time-consuming and not all
hospitals have the proper equipment for autofluorescence
analysis. Our study might very well present an underesti-
mation of the incidence of viable tumor cells retrieved
from the needle applicator, because the absence of tumor
cells on the needle applicator does not mean that viable
tumor cells had not been implanted during the procedure.
On the other hand, dislodgement of viable tumor cells does
not necessarily mean implantation and outgrowth of these
cells in the needle track.
Previous reports that examined needle track implanta-
tion after biopsies in CRLM have shown the possibility of
outgrowth of displaced tumor cells.24,35,36 The finding in
this study that attachment of viable cells to the needle
applicator was associated with a four times higher risk of
LTP and a shorter time to LTP in this study raises serious
concerns. Our study underscores the need for more effec-
tive tools to assess completeness of local ablative therapies
on site to adjust therapy immediately when residual tumor
is detected. Track ablation is recommended in literature but
does not seem to have been completely implemented in
clinical practice as was shown in our study.21,37–40 Because
TABLE 2 Analysis of possible risk factors associated with viable
tumor cells attached to needle applicators of 89 applications
Risk factors Vital tumor cells P
Age (year)
[65 13/42 0.434
\65 7/33
Gender
M 11/45 0.605
F 9/30
Subcapsular
Yes 15/47 0.637
No 10/38
Missing 1/4
Type of tumor
HCC 4/18 0.57
Metastasis 22/71
Differentiation of primary tumor
Good 0/1 0.897
Moderate 17/55
Poor 2/6
Missing 0/1
HCC 7/26
Needle applicator
Radiotherapeutics 17/29 0
RITA 3/16
Radionics 3/28
Laser 3/16
Tumor size
[4 cm 10/32 0.81
\4 cm 16/57
Approach
Open 22/61 0.045
Percutaneous 4/28
Track ablation
Yes 9/58 0
No 17/31
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this study demonstrated that viable tissue adheres to the
needle applicators used with RFA/LITT, coagulation of
needle the track also should be used when the needle
applicator is (re)positioned in (viable) tumor during or
before the ablative procedure. Moreover, this study shows
that viable tumor tissue is found after RFA/LITT even
when track ablation is applied, therefore, protocols for
track ablation should be executed precisely.
TABLE 3 Univariate analysis for possible risk factors associated with time to LTP, DFS, OS (months)
Risk factors TLTP (mean ± SD) P DFS (mean ± SD) P Overall survival (mean ± SD) P
Age
[65 29.13 ± 3.59 0.204 11.39 ± 1.57 0.676 31.86 ± 2.76 0.419
\65 30.22 ± 3.26 12.72 ± 2.51 30.44 ± 2.69
Gender
M 26.65 ± 2.92 0.334 12.92 ± 1.83 0.669 31.12 ± 2.64 0.896
F 35.93 ± 3.97 11.68 ± 2.1 34.012 ± 3.08
Subcapsular
Yes 28.98 ± 3.28 0.429 10.46 ± 1.48 0.142 32.35 ± 2.64 0.917
No 35.32 ± 3.93 14.54 ± 2.34 33.46 ± 3.16
Type of tumor
HCC 34.61 ± 2.796 0.09 17.75 ± 4.10 0.09 31.86 ± 4.59 0.955
Metastasis 30.27 ± 3.066 10.3 ± 1.4 33.58 ± 2.39
Differentiation of primary tumor
Good No events 0.07 No events 0.01 11.11 (1 event) 0.465
Moderate 28.33 ± 4.08 10.3 ± 1.29 33.73 ± 3.03
Poor 12.11 ± 3.28 7.38 ± 1.42 19.8 ± 6.73
HCC 34.13 ± 2.99 17.75 ± 4.1 31.86 ± 4.59
Needle
Radiotherapeutics 29.54 ± 4.35 0.46 13.68 ± 2.52 0.876 32.1 ± 3.46 0.344
RITA 36.23 ± 6.45 11.88 ± 3.38 39.69 ± 5.09
Radionics 31.55 ± 3.92 12.07 ± 2.06 30.49 ± 3.03
Laser 26.66 ± 6.23 11.33 ± 3.91 30.96 ± 5.98
Tumor size
[4 cm 15.25 ± 3.89 0.001 10.98 ± 3.14 0.663 27.94 ± 4.57 0.203
\4 cm 36.22 ± 2.96 12.1 ± 1.59 34.49 ± 2.46
Approach
Open 34.91 ± 3.14 0.219 13.52 ± 1.71 0.228 34.34 ± 2.69 0.443
Percutaneous 22.71 ± 3.69 10.5 ± 2.35 27.34 ± 2.47
Pringle
Yes 28.48 ± 5.65 0.727 10.28 ± 3.26 0.382 31.65 ± 4.81 0.818
No 32.33 ± 2.91 12.94 ± 1.57 33.54 ± 2.34
Track ablation
Yes 32.99 ± 3.39 0.899 10.96 ± 1.76 0.458 33.3 ± 2.75 0.876
No 30.28 ± 3.94 13.75 ± 2.11 32.95 ± 3.06
Cells macroscopically visible
Yes 32.97 ± 3.87 0.907 13.31 ± 2.04 0.543 35.18 ± 3.08 0.404
No 31.49 ± 3.45 11.87 ± 1.89 30.79 ± 2.71
Vital cells
Yes 21.19 ± 3.27 0.038 14.01 ± 2.38 0.323 34.75 ± 3.41 0.538
No 36.34 ± 3.09 11.91 ± 1.71 32.45 ± 2.57
Time to LTP, DFS, and OS are calculated with the Kaplan–Meier method
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CONCLUSIONS
Viable tumor cells adherent to the needle applicators
were found in 26.7% of patients after local tumor ablation.
Adherence of viable tumor cells to the needle applicator
after local ablation was an independent predictor of LTP.
Because the omission of track ablation was the only
independent predictor of the presence of viable cells
attached to the needle applicator, correct track ablation is
mandatory. We recommend only the use of RFA devices
with which track ablation can be applied.
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